Innvolution Healthcare has secured a license to produce cardiac cath labs at the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam [1].

This development marks a shift toward domestic autonomy in high-end medical imaging and intervention technology. By manufacturing these complex systems locally, India aims to reduce its reliance on expensive imports and lower the cost of cardiac care for patients.

The production facility will operate within the AMTZ, a specialized hub designed to accelerate the development of medical devices. The move aligns with the broader goals of the ‘Make in India’ initiative, which encourages the domestic production of advanced technology to strengthen the national industrial base [1].

Cardiac catheterization laboratories are essential for diagnosing and treating cardiovascular diseases. These labs integrate advanced imaging and monitoring equipment to allow physicians to perform minimally invasive procedures on the heart. Producing these systems within Visakhapatnam provides a strategic advantage for distribution across the region.

The license allows Innvolution Healthcare to begin the transition from planning to active manufacturing. This step is expected to create specialized jobs in the med-tech sector, and foster an ecosystem of innovation within the Andhra Pradesh MedTech Zone [1].

By establishing a local production line for cardiac cath labs, the company contributes to the government's vision of transforming India into a global manufacturing hub for medical devices [1].

“Innvolution Healthcare has secured a license to produce cardiac cath labs”

The localization of cardiac cath lab production signifies a strategic move to democratize specialized healthcare. By shifting from an import-heavy model to domestic manufacturing, India can potentially lower the capital expenditure required for hospitals to establish heart centers, thereby increasing the accessibility of life-saving cardiac interventions for a larger segment of the population.